Overview
Fmoc-NH-(PEG)5-CH2CH2COOH is a unique pegylated amino acid designed for peptide synthesis. This compound offers significant advantages in enhancing the solubility and stability of peptides, making it an excellent choice for researchers looking to improve their peptide formulations. By incorporating Fmoc-NH-(PEG)5-CH2CH2COOH, you can achieve better performance in various biological assays and applications. Its flexibility allows for a variety of modifications, enabling you to tailor your peptides to meet specific research needs.
Key Features
- Enhances solubility and stability of peptides
- Facilitates efficient peptide synthesis
- Compatible with a range of amino acids
- Available in a convenient 1 g package
- Ideal for use in research and diagnostic applications
Specifications
| Product Name | Fmoc-NH-(PEG)5-CH2CH2COOH |
| Category | Pegylated Amino Acids & Special Linkers |
| Weight | 1 g |
| CAS Number | Not available |
FAQ
What applications is Fmoc-NH-(PEG)5-CH2CH2COOH suitable for?
This pegylated amino acid is suitable for a variety of applications in peptide synthesis, particularly in research and diagnostic settings. Its properties help to enhance the biological activity and stability of peptides.
How does pegylation improve peptide synthesis?
Pegylation improves peptide synthesis by increasing the solubility and stability of the resulting peptides. This modification helps to maintain the peptide’s integrity during experimentation, leading to more reliable results.
Can I combine Fmoc-NH-(PEG)5-CH2CH2COOH with other amino acids?
Yes, you can combine Fmoc-NH-(PEG)5-CH2CH2COOH with various amino acids and other pegylated compounds, such as Fmoc-PEG2-Suc-OH or Fmoc-AEE Ac-OHto create customized peptides for your research.
Shop now for Fmoc-NH-(PEG)5-CH2CH2COOH and enhance your peptide synthesis projects with this essential tool. You can also explore other products in our Pegylated Amino Acids & Special Linkers category for a complete solution tailored to your research needs.




Reviews
There are no reviews yet.